EP0804438B1 - Tricyclic benzazepine vasopressin antagonists - Google Patents

Tricyclic benzazepine vasopressin antagonists Download PDF

Info

Publication number
EP0804438B1
EP0804438B1 EP96903698A EP96903698A EP0804438B1 EP 0804438 B1 EP0804438 B1 EP 0804438B1 EP 96903698 A EP96903698 A EP 96903698A EP 96903698 A EP96903698 A EP 96903698A EP 0804438 B1 EP0804438 B1 EP 0804438B1
Authority
EP
European Patent Office
Prior art keywords
lower alkyl
pyrrolo
benzodiazepin
pyridine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96903698A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0804438A1 (en
Inventor
Jay Donald Albright
Aranapakam Mudumbai Venkatesan
John Paul Dusza
Fuk-Wah Sum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC filed Critical Wyeth Holdings LLC
Priority to SI9630735T priority Critical patent/SI0804438T1/sl
Publication of EP0804438A1 publication Critical patent/EP0804438A1/en
Application granted granted Critical
Publication of EP0804438B1 publication Critical patent/EP0804438B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Definitions

  • This invention relates to new tricyclic non-peptide vasopressin antagonists which are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction.
  • Vasopressin is released from the posterior pituitary either in response to increased plasma osmolarity detected by brain osmoreceptors or decreased blood volume and blood pressure sensed by low-pressure volume receptors and arterial baroreceptors.
  • the hormone exerts its action through two well defined receptor subtypes: vascular V 1 and renal epithelial V 2 receptors.
  • Vasopressin-induced antidiuresis mediated by renal epithelial V 2 receptors, helps to maintain normal plasma osmolarity, blood volume and blood pressure.
  • Vasopressin is involved in some cases of congestive heart failure where peripheral resistance is increased.
  • V 1 antagonists may decrease systemic vascular resistance, increase cardiac output and prevent vasopressin induced coronary vasoconstriction.
  • V 1- antagonists may be therapeutic agents.
  • V 1 antagonists may decrease blood pressure, induced hypotensive effects and thus be therapeutically useful in treatment of some types of hypertension.
  • V 2 receptors The blockage of V 2 receptors is useful in treating diseases characterized by excess renal reabsorption of free water.
  • Antidiuresis is regulated by the hypothalamic release of vasopressin (antidiuretic hormone) which binds to specific receptors on renal collecting tubule cells. This binding stimulates adenylyl cyclase and promotes the cAMP-mediated incorporation of water pores into the luminal surface of these cells.
  • V 2 antagonists may correct the fluid retention in congestive heart failure, liver cirrhosis, nephritic syndrome, central nervous system injuries, lung disease and hyponatremia.
  • vasopressin levels occur in congestive heart failure which is more common in older patients with chronic heart failure.
  • a V 2 antagonist may be beneficial in promoting free water excretion by antagonizing the action of antidiuretic hormone.
  • antagonists of vasopressin are expected to be therapeutically useful in the treatment and/or prevention of hypertension, cardiac insufficiency, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, congestive heart failure, nephritic syndrome, brain edema, cerebral ischemia, cerebral hemorrhage-stroke, thrombosis-bleeding and abnormal states of water retention.
  • Non-peptide vasopressin antagonists have recently been disclosed, Y. Yamamura et al., Science, 252, 579(1991); Y. Yamamura et al., Br. J . Pharmacol, 105, 787(1992); Ogawa et al., (Otsuka Pharm Co., LTD.) EP 0514667-A1; EPO 382185-A2; WO9105549 and U.S.5,258,510; WO 9404525 Yamanouchi Pharm.Co.,Ltd., WO 9420473; WO 9412476; WO 9414796; Fujisawa Co.
  • EP 620216-A1 Ogawa et al, (Otsuka Pharm. Co.) EP 470514A disclose carbostyril derivatives and pharmaceutical compositions containing the same.
  • Non-peptide oxytocin and vasopressin antagonist have been disclosed by Merck and Co.; M.G. Bock and P.D. Williams, EP 0533242A; M.G. Bock et al., EP 0533244A; J.M. Erb, D.F. Verber, P.D. Williams, EP 0533240A; K. Gilbert et al., EP 0533243A.
  • EP 0636625A discloses tricyclic vasopressin antagonists.
  • Premature birth can cause infant health problems and mortality and a key mediator in the mechanism of labor is the peptide hormone oxytocin.
  • antagonists of this hormone are useful in the prevention of preterm labor, B.E. Evans et al., J. Med. Chem. 35, 3919(1992), J . Med . Chem ., 36, 3993 (1993) and references therein.
  • the compounds of this invention are antagonists of the peptide hormone oxytocin and are useful in the control of premature birth.
  • the present invention relates to novel tricyclic derivatives which exhibit antagonist activity at V 1 and/or V 2 receptors and exhibit in vivo vasopressin antagonist activity.
  • the compounds also exhibit antagonist activity at oxytocin receptors.
  • This invention relates to new compounds selected from those of the general formula I: wherein Y is a moiety selected from; -(CH 2 ) n - wherein n is an integer from 0 to 2, A-B is a moiety selected from wherein m is an integer from 1 to 2 provided that when Y is -(CH 2 ) n - and n is 2, m may also be zero and when n is zero, m may also be three, provided also that when Y is -(CH 2 ) n - and n is 2, m may not be two; and the moiety: represents: (1) phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C 1 -C 3 ) lower alkyl, halogen, amino, (C 1 -C 3 )lower alkoxy or (C 1 -C 3 )lower alkylamino; (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one heteroatom selected from 0,
  • R 3 is the moiety: and Ar is selected from the moieties: Y is (CH 2 ) n and n is one or zero; wherein R 1 , R 2 , R 4 , R 5 , R 6 and R 14 are as hereinbefore defined.
  • R 3 is the moiety: and Ar is selected from the moieties: Y is - (CH 2 ) n and n is one and m is one; wherein R 1 , R 2 , R 4 , R 6 and R 14 are as hereinbefore defined.
  • R 3 is the moiety: and Ar is selected from the moieties: Y is -(CH 2 ) n and n is one or zero; R 6 is wherein cycloalkyl is defined as C 3 -C 6 cycloalkyl, cyclohexenyl or cyclopentenyl; and wherein X, R a , R b and R 14 are as hereinbefore defined; and Ar' is selected from the moieties: wherein R 8 , R 9 and W' are as hereinbefore defined.
  • Y in Formula I is -(CH 2 ) n - and n is zero or one;
  • A-B is and R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 14 are as hereinbefore defined; and m is an integer from 1-2.
  • R 3 is the moiety: Ar is selected from the moieties: R 6 is (CH 2 ) n -cycloalkyl wherein cycloalkyl is defined as C 3 -C 6 cycloalkyl, cyclohexenyl or cyclopentenyl; wherein X, R a , R b and R 14 are as hereinbefore defined; and Ar' is: wherein R 5 , R 8 and R 9 are as previously defined.
  • Y is -(CH 2 ) n - and n is zero or one; wherein the moiety: is a phenyl, substituted phenyl, thiophene, furan, pyrrole or pyridine ring; A-B is: m is one when n is one and m is two when n is zero; D, E, F, R 1 , R 2 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 are as previously defined; R 3 is the moiety: wherein Ar is selected from the moieties: and R 6 is selected from the group: where Ar' is selected from the group: and R 14 , X, W', R a , R b and cycloalkyl are as previously described.
  • R 3 is the moiety: wherein Ar is selected from the moieties: R 6 is and Ar' is selected from the moieties: wherein X, R a , R b , R 5 , R 7 , R 8 , R 9 , R 14 , cycloalkyl and W' are as hereinbefore described;
  • R 11 is selected from hydrogen, halogen, (C 1 -C 3 ) lower alkyl, hydroxy, -CHO, and (C 1 -C 3 )lower alkoxy; and
  • R 12 is selected from hydrogen, (C 1 -C 3 ) lower alkyl, halogen and (C 1 -C 3 ) lower alkoxy.
  • R 3 is the moiety: wherein Ar is selected from the moieties: R 6 is R 14 is wherein n is 0 or 1; R a is hydrogen, -CH 3 or -C 2 H 5 ; R' is hydrogen, (C 1 -C 3 )lower alkyl, (C 1 -C 3 )lower alkoxy and halogen; R 20 is hydrogen, halogen, (C 1 -C 3 )lower alkyl, (C 1 -C 3 )lower alkoxy, NH 2 , -NH(C 1 -C 3 )lower alkyl, -N-[(C 1 -C 3 )lower alkyl] 2 , wherein cycloalkyl is defined as C 3 -C 6 cycloalkyl, cyclohexenyl or cyclopentenyl; R b is hydrogen; R a is independently selected from hydrogen, -CH 3 , -C 2 H 5 or
  • R 3 is the moiety: wherein Ar is selected from the moieties: R 6 is wherein cycloalkyl is defined as C 3 -C 6 cycloalkyl, cyclohexenyl or cyclopentenyl; R b is hydrogen; R a is independently selected from hydrogen, -CH 3 , -C 2 H 5 or -(CH 2 ) q N(CH 3 ) 2 : and Ar' is selected from the moieties: wherein q, X, R a , R b , R 5 , R 7 , R 8 , R 9 , R 11 , R 14 and W' are as hereinbefore defined; R 12 and R 13 are independently selected from hydrogen, (C 1 -C 3 ) lower alkyl, halogen, amino, (C 1 -C 3 ) lower alkoxy or (C 1 -C 3 ) lower alkylamino.
  • Compounds of this invention may be prepared as shown in Scheme I by reaction of tricyclic derivatives of Formula 3a and 3b with a substituted or unsubstituted 6-nitropyridine-3-carbonyl chloride 4 to give the intermediates 5a and 5b .
  • Reduction of the nitro group in intermediates 5a and 5b gives the 6-aminopyridine derivatives 6a and 6b .
  • the reduction of the nitro group in intermediates 5a and 5b may be carried out under catalytic reduction conditions (hydrogen-Pd/C; Pd/C-hydrazine-ethanol) or under chemical reduction conditions (SnCl 2 -ethanol; Zn-acetic acid TiCl 3 ) and related reduction conditions known in the art for converting a nitro group to an amino group.
  • the conditions for conversion of the nitro group to the amino group are chosen on the basis of compatability with the preservation of other functional groups in the molecule.
  • the compounds of Formula I wherein Y, A-B, Z, R 1 , R 2 and R 3 are as defined and the Ar moiety of R 3 (-COAr) is may be prepared, as shown in Scheme 4, by reacting an activated ester of the pyridine-3-carboxylic acid 14 with tricyclic derivatives 3a and 3b .
  • the pyridine-3-carboxylic acids 14 may be activated by preparing the anhydride, a mixed anhydride or reacting with diethyl cyanophosphonate, N , N -carbonyldiimidazole or related peptide coupling reagents.
  • the acid chloride derivatives 15 may be prepared from the acid derivatives 14 and oxalyl chloride or thionyl chloride in an inert solvent. The solvent is removed and the derivative reacted with 3a or 3b at 0°C to 25°C in dichloromethane as solvent and a tertiary amine such as triethylamine as a base.
  • the activating reagent for the pyridine-3-carboxylic acids 14 is chosen on the basis of its compatibility with other substituent groups and the reactivity of the activated derivative toward the tricyclic-derivatives 3a and 3b to give the vasopressin antagonists 16a and 16b .
  • the compounds of Formula I wherein Y, A-B, Z, R 1 , R 2 and R 3 are as defined and the Ar moiety of R 3 (-COAr) is wherein R 6 is the moiety -X-R 7 and X is S, NH, NCH 3 may be prepared as shown in Scheme 5 by first converting tricyclic derivatives 3a and 3b into the intermediates 17a and 17b and then reacting these intermediates with potassium, sodium, or lithium anions (R 7 -X - ) to give the products 16a and 16b .
  • M + is a metal cation derived from reacting a compound HXR 7 with a metal hydride (sodium or potassium hydride, for example) or LDA, n-butyl lithium, lithium bis(trimethylsilyl)amide and the like.
  • a metal hydride sodium or potassium hydride, for example
  • LDA lithium bis(trimethylsilyl)amide
  • intermediates 17a and 17b with the moieties R 7 -NH 2 and R 7 -NHCH 3 may also be carried without first forming the corresponding anions.
  • heating intermediates 17a and 17b with excess R 7 -NH 2 or R 7 -NHCH 3 in an inert solvent or without solvent gives the products 16a and 16b wherein X is NH or NCH 3 .
  • the intermediates 17a and 17b may be converted to the more reactive fluoride derivatives 18a and 18b as shown in Scheme 6 .
  • Reaction of the fluoride intermediates 18a and 18b with amines NH 2 R 7 and CH 3 NHR 7 gives the 6-aminonicotinoyl derivatives 19a and 19b .
  • the pyridine carboxylic acids are activated for coupling by conversion to an acid chloride, bromide or anhydride or by first reacting with an activating reagent such as N , N -dicyclocarbodiimide, diethyl cyanophosphonate and related "peptide type" activating reagents.
  • an activating reagent such as N , N -dicyclocarbodiimide, diethyl cyanophosphonate and related "peptide type" activating reagents.
  • the method of activating the acids 20 for coupling to the tricyclic derivatives 3a and 3b is chosen on the basis of compatibility with other substituent groups in the molecule.
  • the method of choice is the conversion of the 3-pyridinyl carboxylic acids 20 to the corresponding 3-pyridinylcarbonyl chlorides.
  • the 3-pyridinylcarbonyl chlorides 22 may be prepared by standard procedures known in the art, such as reaction with thionyl chloride, oxalyl chloride and the like.
  • the coupling reaction is carried out in solvents such as halogenated hydrocarbons, toluene, xylene, tetrahydrofuran, or dioxane in the presence of pyridine or tertiary bases such as triethylamine and the like (Scheme 7).
  • the 3-pyridinylcarbonyl chlorides 22 prepared from the carboxylic acids 20 , may be reacted with derivatives 3a and 3b in pyridine with or without 4-(dimethylamino)pyridine.
  • the intermediate amino acid derivative 27 is first isolated and then ring closed.
  • the cyclic lactams 28 are conveniently reduced with diborane or lithium aluminum hydride to give intermediates 29 .
  • Tricyclic derivatives of structural type 36 may be prepared as shown in Scheme 9. Formylation of 32 under known conditions in the literature, such as Vilsmeier formylation, gives intermediates 35 which on reduction and ring closure affords tricyclics 37 .
  • ring containing the symbol Z is a substituted or unsubstituted phenyl group
  • the procedure gives 4,5-dihydropyrrolo[1,2-a]-quinoxalines 36 .
  • These derivatives 36 and 37 may be reacted with aroyl chlorides (ArCOCl) wherein Ar is as previously defined or with a substituted or unsubstituted 6-nitropyridine-3-carbonyl chloride or with a nitrogen protecting group, such as benzyloxycarbonyl chloride to give compounds 38 and 39 .
  • ArCOCl aroyl chlorides
  • the compounds 38 and 39 may be reacted with chlorine, bromine or halogenating reagents such as N-chlorosuccinimide, N-bromosuccinimide and the like to give compounds 40 and 41 wherein R 17 is a halogen atom.
  • the derivatives 38 and 39 may be formylated and acetylated to give products 40 and 41 wherein R 17 is a CHO or a -COCH 3 group.
  • Halogenation, formylation and acetylation of derivatives 36 gives 1-substituted 4,5-dihydropyrrolo[1,2-a]quinoxalines.
  • R 3 is the moiety: and the Ar group is the moiety: and R 6 , R a , R b , Y, R 1 , R 2 , Z and Ar' are as previously defined and wherein R 11 is selected from the moieties: and may be synthesized as shown in Scheme 10.
  • the tricyclic pyrrolodiazepines 46 and 47 are reacted with appropriate amines in the presence of formaldehyde to give the aminomethylene derivatives 48 and 49 .
  • the reaction may be carried out with aqueous formaldehyde or its equivalent in the presence of the appropriate amine in a lower alkanol at room temperature or preferably at temperatures of 50°C-100°C.
  • the aminomethylene derivatives 48 and 49 may be converted to hydrochloride salts or succinic acid and maleic acid salts as well as other pharmaceutically acceptable acid salts.
  • reaction of tricyclic derivatives of Formula 3a and 3b with substituted and unsubstituted arylcarbonyl chlorides 50, wherein R 1 , R 2 and R 14 are hereinbefore defined gives compounds 51 and 52 which are vasopressin antagonists.
  • Reaction of tricyclic derivatives of Formula 3a and 3b with a substituted or unsubstituted phenyl carbonyl chloride 53 gives intermediates 54a and 54b .
  • the reduction of the nitro group in intermediates 54a and 54b may be carried out under catalytic reduction conditions (hydrogen-Pd/C; Pd/C-hydrazine-ethanol) or under chemical reduction conditions (SnCl 2 -ethanol; Zn-acetic acid TiCl 3 ) and related reduction conditions known in the art for converting a nitro group to an amino group.
  • the conditions for conversion of the nitro group to the amino group are chosen on the basis of compatability with the preservation of other functional groups in the molecule.
  • the acid chlorides R 25 COCl are those wherein R 25 is selected from the group
  • n is 0 or 1;
  • R a is hydrogen, -CH 3 or -C 2 H 5 ;
  • R' is hydrogen, (C 1 -C 3 )lower alkyl, (C 1 -C 3 )lower alkoxy and halogen;
  • R 20 is hydrogen, halogen, (C 1 -C 3 )-lower alkyl, C 1 -C 3 )lower alkoxy, NH 2 , -NH(C 1 -C 3 )-lower alkyl, -N-((C 1 -C 3 )lower alkyl] 2 ,
  • Decroix is 5-oxo-4,5-dihydropyrrolo [1,2-a] thieno [3,2-e] [1,4] diazepine which is also reduced to give 4,10-dihydro-5H-pyrrolo-[1,2-a] thieno [3,2-e] [1,4] diazepine Reported by B. Decroix and J. Morel, J. Het. Chem ., 28 , 81(1991) are 5 H -pyrrolo[1,2-a]thieno[3,2-e][1,4]diazepine; and 4H-pyrrolo[1,2-a]thieno[2,3-e][1,4]diazepine.
  • a mixture of 30.6 g of 1-(2-nitrobenzyl)-2-pyrrolecarboxaldehyde and 3.06 g of 10% Pd/C in 400 ml of ethyl acetate and 400 ml of ethyl alcohol is hydrogenated over 18 hours.
  • the reaction mixture is filtered through diatomaceous earth and the filtrate is treated with activated carbon and filtered through diatomaceous earth.
  • the filtrate is concentrated in vacuo to give a residue which is dissolved in methylene chloride containing ethyl alcohol.
  • a 5.0 g sample of 1-(o-nitrobenzyl)-imidazole-2-carboxaldehyde is dissolved in 150 ml of hot ethyl alcohol, cooled to room temperature and filtered. To the filtrate is added 0.5 g of 10% Pd/C and the mixture hydrogenated at 48 psi for 4 hours. An additional 0.5 g of 10% Pd/C is added and hydrogenation continued for 25 hours at 65 psi. The mixture is filtered through diatomaceous earth and the cake washed with ethyl acetate.
  • the filtrate is evaporated in vacuo to a residue which is dissolved in methylene chloride, treated with activated carbon, filtered through diatomaceous earth and hexanes added to the filtrate at the boil to give 1.86 g of the desired product as a crystalline solid, m.p. 164-170°C.
  • the preceding compound (0.362 g) is added to an ice-water cooled solution of 1 M diborane in tetrahydrofuran. The mixture is stirred at room temperature for 65 hours. The solution is concentrated to dryness and ice-water added to the residue. The mixture is acidified with dilute HCl, stirred and then basified with solid NaHCO 3 . The mixture is filtered to give 0.223 g of a solid (foam) m.p. 80-85°C.
  • a mixture of 2.2 g of 2-cyanoaniline, 2.0 g of methyl bromoacetate and 1.3 g of potassium carbonate in 12 ml of dry N,N-dimethylformamide is heated at 150-155°C for 40 minutes.
  • the cooled mixture is poured into ice-water and the mixture filtered to give 2 g of methyl [N- (2-cyanophenyl) amino] acetate as a yellow solid, m.p. 70-78°C.
  • the preceding compound (2.0 g) is added to a solution of 0.5 g of sodium methoxide in 50 ml of methanol.
  • the mixture is shaken under an atmosphere of hydrogen with the catalyst Raney-Ni for 19 hours.
  • a mixture of 30 g of acrylic acid, 33 g of o- phenylenediamine is heated on a steam bath for 1.5 hours and the cooled black mixture triturated with ice-water.
  • the aqueous phase is decanted and ice and aqueous ammonium hydroxide added to the residue.
  • the mixture is extracted with dichloromethane and the extract concentrated to dryness.
  • the residue is triturated with carbon tetrachloride and filtered.
  • the oily solid is triturated with a small amount of ethanol to give 9.7 g of a solid. Trituration of the solid with ethyl acetate gives 2,3,4,5-tetrahydro-1 H -1,5-benzodiazepin-2-one as an impure solid, m.p. 75-107°C.
  • Example 28 The conditions of Example 28 are used with ethyl 3-nitro-4-bromomethylbenzoate to give 13.0 g of the desired product as a solid; mass spectrum (M + H)349.
  • a mixture of 4.0 g of methyl-2-methylfurane-3-carboxylate, 30 ml of 2 N NaOH and 15 ml methanol is refluxed for 1.5 hours.
  • the solvent is removed under vacuum to give a solid.
  • the solid is extracted with dichloromethane (discarded).
  • the solid is dissolved in water and the solution acidified with 2 N citric acid to give a solid.
  • the solid is washed with water and dried to give crystals 1.05 g of crystals of 2-methylfuran-3-carboxylic acid.
  • the preceding compound (0.95 g) and 3 ml of thionyl chloride is refluxed for 1 hour.
  • the solvent is removed, toluene added (20 ml, three times) and the solvent removed to give the product as an oil.
  • the mixture is filtered through diatomaceous earth and then filtered through a thin pad of hydrous magnesium silicate.
  • the filtrate is diluted with water, the organic layer separated, washed 2 times with 100 ml of water and once with 100 ml of brine and then dried (Na 2 SO 4 ).
  • the solvent is removed under vacuum to give 16 g of solid.
  • the solid is chromatographed on a silica gel column with hexane-ethyl acetate (2:1) as solvent to give crystals which are recrystalizzed from ethyl acetate-hexane (97:3) to give 8.5 g of product as crystals, m.p. 122°-125°C.
  • 6-Amino-5-bromopyridine-3-carboxylic acid (10 g, 50 mmol) is dissolved in saturated methanolic HCl (100 ml) and refluxed for 24 hours. The solvent, methanol, is removed under reduced pressure and the residue is dissolved in ice cold water. The aqueous solution is neutralized with 0.1 N NaOH and the solid which separates is filtered; washed well with water and air dried to yield 10 g of product as a solid: mass spectrum 231 (M + ).
  • the residue (9.0 g) is purified by chromatography on silica gel with hexane-ethyl acetate (3:1) as eluent to give 0.70 g of methyl 6-[[bis(2-methylbenzeneacetyl)]amino]pyridine-3-carboxylate and 8.6 g of a mixture of methyl 6-[(2-methylbenzeneacetyl)amino]pyridine-3-carboxylate and the bis acylated product.
  • the above mixture (8.6 g) of mono and bis acylated product is dissolved in 60 ml of tetrahydrofuran-methanol (1:1) and 23 ml of 5 N NaOH is added. The solution is stirred at room temperature for 16 hours, concentrated under vacuum, diluted with 25 ml of H 2 O and acidified with cold 1 N HCl. The precipitated solid is filtered off and dried to give 5.9 g of white solid.
  • reaction mixture is stirred at room temperature for 18 hours and washed with water, and saturated aqueous NaHCO 3 and the organic layer dried (Na 2 SO 4 ).
  • the organic layer is passed through hydrous magnesium silicate and hexane added to the filtrate at the boil to give 8.38 g of the desired product as a crystalline solid, m.p. 163-165°C.
  • a mixture of 5.0 g of 2-(phenylmethyl)benzoic acid in 5.0 ml of thionyl chloride is heated on a steam bath for 1 hour. The volatiles are evaporated in vacuo to give 5.70 g of an oil.
  • a 2.85 g portion of the above oil in 25 ml of methylene chloride is added to a solution of 50 ml of methylene chloride containing 1.85 g of methyl 4-amino-2-chlorobenzoate and 1.65 g of N,N-diisopropylethylamine by stirring at room temperature for 18 hours.
  • the reaction mixture is washed with water, saturated aqueous NaHCO 3 and the organic layer dried(Na 2 SO 4 ).
  • a mixture of thionyl chloride (100 ml) and 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carboxylic acid (2.7 g, 10 mmol) is heated to reflux for 5 hours. At the end, excess thionyl chloride is removed and the acid chloride is dissolved in CH 2 Cl 2 (100 ml). At room temperature, the methylene chloride solution of the 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carbonyl chloride is added slowly. The reaction mixture is stirred at room temperature for 2 hours and quenched with ice cold water. The reaction mixture is washed with 0.1 N NaOH and subsequently washed with water.
  • the CH 2 Cl 2 layer is separated; dried (MgSO 4 ), filtered and concentrated.
  • the product is purified by silica gel column chromatography by eluting first with 10% ethyl acetate-hexane (1 L) and then with 30% ethyl acetate-hexane. The product is crystallized from ethyl acetate-hexane. Yield 1.0 g, 46 ; mass spectrum (FAB), M + 1 441; M + Na: 462.
  • Example 120 The following Examples are prepared as described for Example 120 with formaldehyde and the appropriate amine.
  • Example 130 As described for Example 130, a solution of 2 mmol of 10-[[6-[2-(dimethylamino)methylamino]-3-pyridinyl]carbonyl]-10,11-dihydro-5 H -pyrrolo[2,1- c ][1,4]-benzodiazepine, 8 ml of diisopropylethylamine, and 2.2 mmol of 5-fluoro-2-methylbenzoyl chloride in 100 ml of dichloromethane is stirred at room temperature for 16 hours. The solvent is removed and the product purified by chromatography on silica gel to give a solid.
  • the organic layer is dried (Na 2 SO 4 ) and passed through a thin pad of hydrous magnesium silicate and the pad washed with dichloromethane.
  • the filtrate is concentrated and the residue chromatographed on silica gel prep-plates with ethyl acetate-hexane (1:1) as eluent.
  • the product is crystallized from ethyl acetate to give 0.38 g of white crystals, m.p. 226-234°C.
  • Example 134 As described for Example 134 the following compounds are prepared (Table F).
  • the solution is filtered through a thin pad of hydrous magnesium silicate and the pad washed with dichloromethane.
  • the filtrate is concentrated and the residue purified on silica gel prep-plates with ethyl acetate-hexane (1:1) as solvent to give a solid.
  • the solid is crystallized from ethyl acetate to give 0.38 g of crystals, m.p. 190-196°C.
  • the mixture is diluted with 60 ml of dichloromethane and washed with 25 ml each of H 2 O, 1 M NaHCO 3 , brine and dried (Na 2 SO 4 ).
  • the solution is filtered (twice) through a thin pad of hydrous magnesium silicate and the pad washed with dichloromethane.
  • the filtrate is concentrated to give a yellow glass (0.68 g) which is crystallized from ethyl acetate to give 0.38 g of white crystals, m.p. 250-260°C; mass spectrum (FABL) 442.4 (M+H).
  • the solution is filtered through a thin pad of hydrous magnesium silicate.
  • the filtrate is concentrated to dryness under vacuum to give 0.4 g of solid.
  • the solid is purified on silica gel prep-plates with ethyl acetate-hexane (3:1) as eluent to give 170 mg of a brown glass, m.p. 110-150°C.
  • a mixture of 0.16 g of 10-[(6-chloro-3-pyridinyl)carbonyl]-10,11-dihydro-5 H -pyrrolo[2,1- c ]-[1,4]benzodiazepine, 40 mg of pyridine and 2 ml of 2-methylpropylamine is stirred and heated at 100°C in a sealed vessel for 1 hour.
  • To the mixture is added 0.2 ml of N,N-dimethylpropyleneurea and the mixture is heated at 110°C for 7 hours.
  • the volatiles are removed under vacuum and 10 ml of 0.5 N NaOH is added to the residue.
  • the mixture is filtered and the solid washed with water and then hexane.
  • the organic layer is passed through hydrous magnesium silicate and the filtrate concentrated in vacuo to give a residue which is dissolved in methylene chloride and passed through hydrous magnesium silicate two additional times to give upon concentration in vacuo 2.87 g of the desired product as an amorphous compound.
  • a mixture of 2.5 g of 6-1[3-(2-methylpyridinyl)carbonyl]amino]pyridine-3-carboxylic acid and 25 ml of thionyl chloride is refluxed for 3 hours and the mixture evaporated to dryness in vacuo to give a solid.
  • a solution of the solid in 50 ml of methylene chloride is added to 2 g of 10,11-dihydro-5 H -pyrrolo-[2,1- c ][1,4]benzodiazepine dissolved in 50 ml of dichloromethane containing 3 ml of N,N-diisopropylethylamine at room temperature.
  • reaction mixture is stirred at room temperature for 2 hours and quenched with water; washed with water; dried(MgSO 4 ), filtered and evaporated in vacuo to a residue.
  • Example 343 4-(n-pentyloxy)benzoyl chloride is reacted with 10,11-dihydro-5 H- pyrrolo[2,1- c ] [1,4]benzodiazepine to the desired product as a solid:mass spectrum(CI), 375(MH + ).
  • Example 325 The conditions of Example 325 are used with 2-(4-chlorophenoxy)-2-methylpropionyl chloride to give the desired product as a solid. M+499.
  • Example 86 Using the conditions of Example 1 with Reference Example 39 to give Reference Example 86 and stirring overnight gives the desired product as white crystals after column chromatography on silica gel by elution with 1:1 ethyl acetate:hexane and crystallization from ethyl acetate, m.p. 210-212°C.
  • a room temperature solution of 1.0 g of N-[5-(5 H -pyrrolo[2,1- c ] [1,4]benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl]-2-nitrobenzamide in 100 ml of ethyl alcohol is hydrogenated over 200 mg of 10% Pd/C in a Parr apparatus under 40 psi of hydrogen for 2 hours.
  • the reaction mixture is filtered through diatomaceous earth and the cake washed with additional ethyl alcohol.
  • the combined filtrates are concentrated in vacuo and the residue purified by crystallization from 2:1 ethyl acetate:hexane to give the desired product as pale yellow crystals: M+Na 445:M + 423.
  • Rat liver plasma membranes expressing the vasopressin V 1 receptor subtypes are isolated by sucrose density gradient according to the method described by Lesko et al, (1973). These membranes are quickly suspended in 50.0 mM Tris.HCl buffer, pH 7.4, containing 0.2% bovine serum albumin (BSA) and 0.1 mM phenylmethylsulfonylfluoride (PMSF) and kept frozen at -70°C until used in subsequent binding experiments.
  • BSA bovine serum albumin
  • PMSF phenylmethylsulfonylfluoride
  • the radioactivity trapped on the filter disk by the ligand-receptor complex is assessed by liquid scintillation counting in a Packard LS Counter, with an efficiency of 65% for tritium.
  • the data are analyzed for IC 50 values by the LUNDON-2 program for competition (LUNDON SOFTWARE, OH).
  • Medullary tissues from rat kidneys are dissected out, cut into small pieces and soaked in a 0.154 mM sodium chloride solution containing 1.0 mM EDTA with many changes of the liquid phase, until the solution is clear of blood.
  • the tissue is homogenized in a 0.25 M sucrose solution containing 1.0 mM EDTA and 0.1 mM PMSF using a Potter-Elvehjem homogenizer with a teflon pestle.
  • the homogenate is filtered through several layers (4 layers) of cheese cloth.
  • the filtrate is rehomogenized using a dounce homogenizer, with a tight fitting pestle.
  • the final homogenate is centrifuged at 1500 x g for 15 min.
  • the nuclear pellet is discarded and the supernatant fluid recentrifuged at 40,000 x g for 30 min.
  • the resulting pellet formed contains a dark inner part with the exterior, slightly pink.
  • the pink outer part is suspended in a small amount of 50.0 mM Tris.HCl buffer, pH 7.4.
  • the protein content is determined by the Lowry's method (Lowry et al, J. Biol. Chem., 1953).
  • the membrane suspension is stored at -70°C, in 50.0 mM Tris.HCl, containing 0.2% inactivated BSA and 0.1 mM PMSF in aliquots of 1.0 ml containing 10.0 mg protein per ml of suspension until use in subsequent binding experiments.
  • the radioactivity trapped on the filter disk by the ligand-receptor complex is assessed by liquid scintillation counting in a Packard LS Counter, with an efficiency of 65% for tritium.
  • the data are analyzed for IC 50 values by the LUNDON-2 program for competition (LUNDON SOFTWARE, OH). The results of this test on representative compounds of this invention are shown in Tables 1, 2 and 3.
  • Platelet Source Hudson Valley Blood Services, Westchester Medical Center, Valhalla, NY.
  • Frozen platelet rich plasma received from the Hudson Valley Blood Services, are thawed to room temperature.
  • the tubes containing the PRP are centrifuged at 16,000 x g for 10 min. at 4°C and the supernatant fluid discarded.
  • the platelets resuspended in an equal volume of 50.0 mM Tris.HCl, pH 7.5 containing 120 mM NaCl and 20.0 mM EDTA.
  • the suspension is recentrifuged at 16,000 x g for 10 min. This washing step is repeated one more time.
  • the homogenate is centrifuged at 39,000 x g for 10 min.
  • the resulting pellet is resuspended in Tris.HCl buffer, 70.0 mM, pH 7.5 and recentrifuged at 39,000 x g for 10 min.
  • the final pellet is resuspended in 50.0 mM Tris.HCl buffer pH 7.4 containing 120 mM NaCl and 5.0 mM KCl to give 1.0-2.0 mg protein per ml of suspension.
  • Flasks of 175 ml capacity, containing attached cells grown to confluence, are cleared of culture medium by aspiration.
  • the flasks containing the attached cells are rinsed with 2x5 ml of phosphate buffered saline (PBS) and the liquid aspirated off each time.
  • PBS phosphate buffered saline
  • 5 ml of an enzyme free dissociation Hank's based solution (Specialty Media, Inc., Lafayette, NJ) is added and the flasks are left undisturbed for 2 min.
  • the content of all flasks is poured into a centrifuge tube and the cells pelleted at 300 x g for 15 min.
  • the Hank's based solution is aspirated off and the cells homogenized with a polytron at setting #6 for 10 sec in 10.0 mM Tris.HCl buffer, pH 7.4 containing 0.25 M sucrose and 1.0 mM EDTA.
  • the homogenate is centrifuged at 1500 x g for 10 min to remove ghost membranes.
  • the supernatant fluid is centrifuged at 100,000 x g for 60 min to pellet the receptor protein. Upon completion, the pellet is resuspended in a small volume of 50.0 mM Tris.HCl buffer, pH 7.4.
  • the protein content is determined by the Lowry method and the receptor membranes are suspended in 50.0 mM Tris.HCl buffer containing 0.1 mM phenylmethylsulfonylfluoride (PMSF) and 0.2% bovine serum albumin (BSA) to give 2.5 mg receptor protein per ml of suspension.
  • PMSF phenylmethylsulfonylfluoride
  • BSA bovine serum albumin
  • the radioactivity trapped on the filter disk by the ligand-receptor complex is assessed by liquid scintillation counting in a Packard LS Counter, with an efficiency of 65% for tritium.
  • the data are analyzed for IC 50 values by the LUNDON-2 program for competition (LUNDON SOFTWARE, OH).
  • mice Female Sprague-Dawley rats weighing approximately 200-250 g are injected intramuscularly (i.m.) with 0.3 mg/kg of body weight of diethylstilbestrol (DES). The rats are sacrificed 18 hours later under pentobarbital anesthesia. The uteri are dissected out, cleaned of fat and connective tissues and rinsed in 50 ml of normal saline. The tissue pooled from six rats is homogenized in 50 ml of 0.01 mM Tris.HCl, containing 0.5 mM dithiothreitol and 1.0 mM EDTA, adjusted to pH 7.4, using a polytron at setting 6 with three passes of 10 sec each.
  • DES diethylstilbestrol
  • the homogenate is passed through two (2) layers of cheesecloth and the filtrate centrifuged at 1000 x g for 10 min. The clear supernatant is removed and recentrifuged at 165,000 x g for 30 min. The resulting pellet containing the oxytocin receptors is resuspended in 50.0 mM Tris.HCl containing 5.0 mM MgCl 2 at pH 7.4, to give a protein concentration of 2.5 mg/ml of tissue suspension. This preparation is used in subsequent binding assays with [ 3 H] Oxytocin.
  • Binding of 3,5-[ 3 H]Oxytocin ([ 3 H]OT) to its receptors is done in microtiter plates using [ 3 H]OT, at various concentrations, in an assay buffer of 50.0 mM Tris.HCl, pH 7.4 and containing 5.0 mM MgCl 2 , and a mixture of protease inhibitors: BSA, 0.1 mg; aprotinin, 1.0 mg; 1,10-phenanthroline, 2.0 mg; trypsin, 10.0 mg; and PMSF, 0.3 mg per 100 ml of buffer solution. Non-specific binding is determined in the presence of 1.0 uM unlabeled OT.
  • the binding reaction is terminated after 60 min., at 22°C, by rapid filtration through glass fiber filters using a Brandel® cell harvester (Biomedical Research and Development Laboratories, Inc., Gaithersburg, MD). Competition experiments are conducted at equilibrium using 1.0 nM [ 3 H]OT and varying the concentration of the displacing agents. The concentrations of agent displacing 50% of [ 3 H]OT at its sites (IC 50 ) are calculated by a computer assisted LUNDON-2 program (LUNDON SOFTWARE INC., Ohio, USA).
  • the compounds of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases.
  • These salts include, but are not limited to, the following: salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and maleic acid.
  • Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
  • the compounds can also be used in the form of esters, carbamates and other conventional "pro-drug" forms, which, when administered in such form, convert to the active moiety in vivo.
  • the compounds When the compounds are employed for the above utilities, they may be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium.
  • Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.
  • the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in a sustained release form. For most large mammals the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg.
  • Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes.
  • Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired.
  • Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
  • compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.
  • active compounds may also be administered parenterally or intraperitoneally.
  • Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exits. It must be stable under conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.
  • the new tricyclic non-peptide vasopressin antagonists of this invention are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction.
  • vasopressin antagonists of this invention are therapeutically useful in the treatment and/or prevention of hypertension, cardiac insufficiency, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, congestive heart failure, nephritic syndrome, brain edema, cerebral ischemia, cerebral hemorrhage-stroke, thrombosis-bleeding and abnormal states of water retention.
  • the oxytocin antagonists of this invention are useful in the prevention of preterm labor and premature birth which is a significant cause of infant health problems and infant mortality.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP96903698A 1995-01-17 1996-01-16 Tricyclic benzazepine vasopressin antagonists Expired - Lifetime EP0804438B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI9630735T SI0804438T1 (sl) 1995-01-17 1996-01-16 Triciklicni benzazepinski antagonisti vazopresina

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US373132 1995-01-17
US08/373,132 US5536718A (en) 1995-01-17 1995-01-17 Tricyclic benzazepine vasopressin antagonists
PCT/US1996/001076 WO1996022293A1 (en) 1995-01-17 1996-01-16 Tricyclic benzazepine vasopressin antagonists

Publications (2)

Publication Number Publication Date
EP0804438A1 EP0804438A1 (en) 1997-11-05
EP0804438B1 true EP0804438B1 (en) 2006-03-15

Family

ID=23471110

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96903698A Expired - Lifetime EP0804438B1 (en) 1995-01-17 1996-01-16 Tricyclic benzazepine vasopressin antagonists

Country Status (23)

Country Link
US (3) US5536718A (da)
EP (1) EP0804438B1 (da)
JP (2) JP4163252B2 (da)
KR (1) KR100443438B1 (da)
CN (1) CN1065244C (da)
AR (1) AR002022A1 (da)
AT (1) ATE320429T1 (da)
AU (1) AU707982B2 (da)
BR (1) BR9607182A (da)
CZ (1) CZ297797B6 (da)
DE (1) DE69635922T2 (da)
DK (1) DK0804438T3 (da)
EA (1) EA001143B1 (da)
ES (1) ES2258267T3 (da)
HU (1) HUP9800646A3 (da)
IL (1) IL116775A (da)
MX (1) MX9705313A (da)
NZ (1) NZ302111A (da)
PT (1) PT804438E (da)
TW (1) TW403752B (da)
UA (1) UA54383C2 (da)
WO (1) WO1996022293A1 (da)
ZA (1) ZA96297B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736540A (en) * 1993-07-29 1998-04-07 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US7071133B2 (en) * 1993-11-16 2006-07-04 Ppg Industries Ohio, Inc. Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift
DK0764157T3 (da) * 1994-06-10 2002-04-22 Smithkline Beecham Plc Benzopyraner og deres anvendelse som terapeutiske midler
BR9509055A (pt) * 1994-09-30 1998-06-23 Basf Ag Imidazoloquinoxalinona uso da mesma e composiçao farmacêutica
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5700796A (en) * 1995-01-17 1997-12-23 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5880122A (en) * 1996-11-01 1999-03-09 American Home Products Corporation 3-Carboxamide derivatives of 5H-pyrrolo 2,1-c! 1,4!-benzodiazepines
US20020155299A1 (en) 1997-03-14 2002-10-24 Harris Caroline S. Photo-induced hydrophilic article and method of making same
US20030039843A1 (en) * 1997-03-14 2003-02-27 Christopher Johnson Photoactive coating, coated article, and method of making same
US7096692B2 (en) * 1997-03-14 2006-08-29 Ppg Industries Ohio, Inc. Visible-light-responsive photoactive coating, coated article, and method of making same
EP0987266A4 (en) * 1997-03-31 2000-07-26 Wakamoto Pharma Co Ltd BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
AU6955998A (en) * 1997-04-15 1998-11-11 Eli Lilly And Company Method for providing neuro-protective effects
US6511974B1 (en) 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
US6194407B1 (en) 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
US6235900B1 (en) 1999-02-04 2001-05-22 American Home Products Corporation Tricyclic pyridine N-oxides vasopressin agonists
US6297234B1 (en) 1999-02-04 2001-10-02 American Home Products Corporation Arylthiophene vasopressin agonists
CN1391476A (zh) * 1999-09-27 2003-01-15 美国氰胺公司 血管升压素激动剂制剂和方法
CN1635890A (zh) * 2000-08-08 2005-07-06 奥索-麦克尼尔药品公司 神经保护性2－吡啶胺组合物和相关方法
US20050203092A1 (en) * 2000-08-08 2005-09-15 Benjamin Elfrida R. 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
US7323249B2 (en) * 2000-08-31 2008-01-29 Ppg Industries Ohio, Inc. Methods of obtaining photoactive coatings and/or anatase crystalline phase of titanium oxides and articles made thereby
US6677063B2 (en) 2000-08-31 2004-01-13 Ppg Industries Ohio, Inc. Methods of obtaining photoactive coatings and/or anatase crystalline phase of titanium oxides and articles made thereby
US7064120B2 (en) * 2001-04-12 2006-06-20 Wyeth Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US6977254B2 (en) * 2001-04-12 2005-12-20 Wyeth Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US7326700B2 (en) * 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7109193B2 (en) 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
JP2004530668A (ja) * 2001-04-12 2004-10-07 ワイス バソプレッシンアゴニストとしてのｎ−ビフェニルカルボニル−およびｎ−フェニルピリジルカルボニル置換二および三環アゼピンおよびジアゼピン
CN1294134C (zh) * 2001-04-12 2007-01-10 惠氏公司 环己基苯基血管升压素激动剂
US7202239B2 (en) * 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7232615B2 (en) * 2001-10-22 2007-06-19 Ppg Industries Ohio, Inc. Coating stack comprising a layer of barrier coating
US20040010010A1 (en) * 2002-04-30 2004-01-15 Ebetino Frank Hallock Melanocortin receptor ligands
EP1603858A2 (en) * 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
US20060029754A1 (en) * 2004-08-05 2006-02-09 Medwick Paul A Coated substrate with improved solar control properties
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
US20060046089A1 (en) * 2004-09-01 2006-03-02 O'shaughnessy Dennis J Metal based coating composition and related coated substrates
US7947373B2 (en) * 2004-10-14 2011-05-24 Pittsburgh Glass Works, Llc High luminance coated glass
US7563793B2 (en) * 2004-12-20 2009-07-21 Wyeth Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents
US7473471B2 (en) * 2005-03-21 2009-01-06 Ppg Industries Ohio, Inc. Coating composition with solar properties
NZ575512A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
UY30117A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
US7998586B2 (en) 2008-11-19 2011-08-16 Ppg Industries Ohio, Inc. Undercoating layers providing improved topcoat functionality
US8133599B2 (en) * 2008-11-19 2012-03-13 Ppg Industries Ohio, Inc Undercoating layers providing improved photoactive topcoat functionality
US20100124642A1 (en) * 2008-11-19 2010-05-20 Ppg Industries Ohio, Inc. Undercoating layers providing improved conductive topcoat functionality
JP5343133B2 (ja) 2008-11-19 2013-11-13 ピーピージー・インダストリーズ・オハイオ・インコーポレイテッド トップコートの機能を向上させるアンダーコーティング層
AR076221A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
US20110146768A1 (en) 2009-12-21 2011-06-23 Ppg Industries Ohio, Inc. Silicon thin film solar cell having improved underlayer coating
US9224892B2 (en) 2009-12-21 2015-12-29 Ppg Industries Ohio, Inc. Silicon thin film solar cell having improved haze and methods of making the same
RU2518102C1 (ru) * 2012-11-01 2014-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Способ получения производных 2-диалкиламинопирроло[1,2-альфа][1,4]бензодиазепина
RU2019120162A (ru) * 2016-12-12 2021-01-12 Де Юниверсити Оф Сидней Непептидные агонисты рецепторов окситоцина
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
KR101798840B1 (ko) * 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
UY37806A (es) 2017-07-11 2020-01-31 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
CA3191811A1 (en) * 2020-09-07 2022-03-10 Hugh ALSOP Salts and crystals

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766108A (en) * 1986-12-04 1988-08-23 Smith Kline Beckman Corporation Tyr-Arg-vasopressin antagonists
US5055448A (en) * 1987-06-25 1991-10-08 Medical College Of Ohio Linear derivatives of arginine vasopressin antagonists
EP0382185B1 (en) * 1989-02-10 1994-06-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
WO1991005549A1 (en) * 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5070187A (en) * 1989-11-03 1991-12-03 Trustees Of Boston University Pharmacologically effective antagonists of arginine-vasopressin
TW199153B (da) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk
JPH04163252A (ja) * 1990-10-25 1992-06-08 Teijin Ltd エアーバッグ
CA2066104C (en) * 1991-04-19 2003-05-27 Hidenori Ogawa Benzazepine derivatives as vasopressin antagonists
CA2110942A1 (en) * 1991-06-14 1992-12-23 Pharmacia & Upjohn Company Llc Imidazo¬1,5-a|quinoxalines
DE69223573D1 (de) * 1991-09-16 1998-01-29 Merck & Co Inc Hydantoin und Succinimid-substituierte Spiroindanylcamphorsulfonyl als Oxytocin-Antagonisten
US5204349A (en) * 1991-09-16 1993-04-20 Merck & Co., Inc. Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
EP0533242A3 (en) * 1991-09-16 1993-09-15 Merck & Co. Inc. Substituted derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
EP0533240A3 (en) * 1991-09-16 1993-09-29 Merck & Co. Inc. Substituted amine derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
EP0612319A1 (en) * 1992-08-20 1994-08-31 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds as oxytocin and vasopressin antagonists
WO1994012476A1 (fr) * 1992-11-25 1994-06-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de benzanilide
WO1994014796A1 (fr) * 1992-12-21 1994-07-07 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive de n-(pyridylcarbonyl)benzazepine et son intermediaire
AU6219994A (en) * 1993-03-11 1994-09-26 Yamanouchi Pharmaceutical Co., Ltd. Compound with vasopressin antagonism
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists

Also Published As

Publication number Publication date
AR002022A1 (es) 1998-01-07
JP4163252B2 (ja) 2008-10-08
EA199700117A1 (ru) 1997-12-30
EP0804438A1 (en) 1997-11-05
CN1198746A (zh) 1998-11-11
BR9607182A (pt) 1997-11-11
UA54383C2 (uk) 2003-03-17
DK0804438T3 (da) 2006-06-12
CZ224997A3 (en) 1997-12-17
KR100443438B1 (ko) 2004-10-14
HUP9800646A3 (en) 1998-12-28
MX9705313A (es) 1998-07-31
DE69635922T2 (de) 2006-08-17
ATE320429T1 (de) 2006-04-15
IL116775A0 (en) 1996-05-14
AU707982B2 (en) 1999-07-22
CN1065244C (zh) 2001-05-02
IL116775A (en) 1999-08-17
EA001143B1 (ru) 2000-10-30
CZ297797B6 (cs) 2007-04-04
US5610156A (en) 1997-03-11
PT804438E (pt) 2006-07-31
NZ302111A (en) 1999-04-29
ZA96297B (en) 1997-07-15
HUP9800646A2 (hu) 1998-08-28
ES2258267T3 (es) 2006-08-16
US5612334A (en) 1997-03-18
US5536718A (en) 1996-07-16
JPH11500106A (ja) 1999-01-06
DE69635922D1 (de) 2006-05-11
JP2008101012A (ja) 2008-05-01
HK1004132A1 (en) 1998-11-20
TW403752B (en) 2000-09-01
AU4769896A (en) 1996-08-07
WO1996022293A1 (en) 1996-07-25

Similar Documents

Publication Publication Date Title
EP0804438B1 (en) Tricyclic benzazepine vasopressin antagonists
EP0636625B1 (en) Tricyclic diazepines vasopressin and oxytocin antagonists
EP0804440B1 (en) Tricyclic benzazepine vasopressin antagonists
AU731925B2 (en) Tricyclic benzazepine vasopressin antagonists
EA000056B1 (ru) Трициклические диазепины в качестве антагонистов вазопрессина, способ их получения и способ лечения с использованием трициклических диазепинов
US5700796A (en) Tricyclic benzazepine vasopressin antagonists
EP1021444B1 (en) 3-CARBOXAMIDE DERIVATIVES OF 5H-PYRROLO[2,1-c][1,4]-BENZODIAZEPINES
WO1997049708A9 (en) Tricyclic benzazepine vasopressin antagonists
HK1004132B (en) Tricyclic benzazepine vasopressin antagonists
CA2210631C (en) Tricyclic benzazepine vasopressin antagonists
GB2174695A (en) Heteroanalogs of imidazobenzodiazepines
HK1011363B (en) Tricyclic diazepines vasopressin and oxytocin antagonists
HK1003891B (en) Tricyclic vasopressin antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970711

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 970711;LV PAYMENT 970711;SI PAYMENT 970711

17Q First examination report despatched

Effective date: 20021115

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH HOLDINGS CORPORATION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Extension state: LT LV SI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060315

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69635922

Country of ref document: DE

Date of ref document: 20060511

Kind code of ref document: P

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1004132

Country of ref document: HK

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20060401780

Country of ref document: GR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Effective date: 20060523

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2258267

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20061218

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: WYETH HOLDINGS CORPORATION

Free format text: WYETH HOLDINGS CORPORATION#FIVE GIRALDA FARMS#MADISON, NJ 07940 (US) -TRANSFER TO- WYETH HOLDINGS CORPORATION#FIVE GIRALDA FARMS#MADISON, NJ 07940 (US)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20080103

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20071212

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20080201

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20081215

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20080116

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20090121

Year of fee payment: 14

Ref country code: IE

Payment date: 20090128

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20090113

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20090122

Year of fee payment: 14

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20090716

LTLA Lt: lapse of european patent or patent extension

Effective date: 20090116

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20090108

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090716

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090116

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20090827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090131

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090804

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20091211

Year of fee payment: 15

Ref country code: ES

Payment date: 20100126

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20100122

Year of fee payment: 15

Ref country code: FR

Payment date: 20100125

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20100129

Year of fee payment: 15

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20100801

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100801

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100118

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100131

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110116

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110116

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69635922

Country of ref document: DE

Effective date: 20110802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110116

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20120220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100116

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110802